13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-09-30 Event 2026-09-28 SEC 0001104659-26-112371 →

BAKER BROS. ADVISORS LP → Kodiak Sciences Inc. KOD

Stake: 35.00% Shares: 22,049,297 CUSIP: 50015M109 Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosures in Item 5 below are incorporated herein by reference. This Amendment No. 12 is being filed to report the acquisition of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of some or all of the Stock Options (as defined below) to purchase Common Stock of the Issuer) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control. Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Cross-References

Insider Activity (last 365d)
3 transactions
0 buys · 0 sales · 3 awards/exercises
Issuer Cluster
9 13D/G filings on this issuer
8 other filings besides this one
Filer Track Record
67 filings by this filer
66 other filings in the data moat
Short Interest · settle 2026-09-30
DTC 1.80
9,376,012 shares short · -12.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $60.59M
Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-09-25 PERLROTH VICTOR director, officer, 10%+ owner Option exercise 600,000 $5.38 $3.23M
2026-09-25 PERLROTH VICTOR director, officer, 10%+ owner Option exercise 365,840 $2.49 $911K
2026-09-25 PERLROTH VICTOR director, officer, 10%+ owner Option exercise 314,684 $3.95 $1.24M

Other 13D/G Filings on Kodiak Sciences Inc.

FiledFormFilerStakeShares
2022-05-18 SC BAKER BROS. ADVISORS LP — — view →
2021-10-01 SC BAKER BROS. ADVISORS LP — — view →
2021-07-26 SC BAKER BROS. ADVISORS LP — — view →
2021-03-05 SC BAKER BROS. ADVISORS LP — — view →
2020-11-24 SC BAKER BROS. ADVISORS LP — — view →
2020-09-08 SC BAKER BROS. ADVISORS LP — — view →
2020-02-26 SC BAKER BROS. ADVISORS LP — — view →
2019-12-06 SC BAKER BROS. ADVISORS LP — — view →

Other Filings by BAKER BROS. ADVISORS LP

FiledFormIssuerStakeShares
2026-09-16 SCHEDULE 13D/A BeOne Medicines Ltd. — 115,457,154 view →
2026-08-11 SCHEDULE 13D/A Replimune Group, Inc. 11.80% 11,075,336 view →
2026-07-16 SCHEDULE 13D/A Celcuity Inc. 9.99% 4,877,963 view →
2026-07-16 SCHEDULE 13G Celcuity Inc. — — view →
2026-06-15 SCHEDULE 13D/A BeOne Medicines Ltd. BEIGF 8.00% 115,457,154 view →
2026-05-26 SCHEDULE 13D/A Kiniksa Pharmaceuticals International, plc KNSA 7.00% 3,231,181 view →
2026-05-11 SCHEDULE 13D/A Incyte Corp INCY — 30,865,077 view →
2025-06-30 SCHEDULE Kymera Therapeutics, Inc. KYMR 9.50% 6,666,540 view →
2024-10-08 SC Kiniksa Pharmaceuticals International, plc KNSA — — view →
2024-06-14 SC INCYTE CORP INCY — — view →
2023-12-18 SC Seagen Inc. — — view →
2023-10-10 SC Neoleukin Therapeutics, Inc. NGNE — — view →
2023-10-05 SC MADRIGAL PHARMACEUTICALS, INC. MDGL — — view →
2023-07-19 SC Neoleukin Therapeutics, Inc. NGNE — — view →
2023-05-24 SC Prelude Therapeutics Inc PRLD — — view →
2023-05-24 SC ACADIA PHARMACEUTICALS INC ACAD — — view →
2023-05-03 SC Seagen Inc. — — view →
2023-03-15 SC INCYTE CORP INCY — — view →
2023-03-13 SC Seagen Inc. — — view →
2023-01-17 SC ACADIA PHARMACEUTICALS INC ACAD — — view →
Showing 20 of 66

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →